Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,459 signal articles · 145 in last 24h · 154,156 total before filter · latest 1h ago
145last 24h
873last 7d
145● bullish (7d)
96● bearish (7d)
214publishers
AllMacro211Earnings107M&A125Regulatory21Product21Analyst17
✕ clear all filtersticker: PFEsentiment: bearishSentiment:bullishneutralbearishshow all (incl. clickbait)
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Reuters71d agobearish
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.